Fact sheet updated August 2017

Genmab

To improve the lives of patients by creating & developing innovative antibody products

2 marketed products
DARZALEX® marketed in the US, Europe & other countries
Arzerra® marketed globally

2 proprietary technologies
DuoBody® bispecific platform
HexaBody® technology

>20 pre-clinical projects
Extensive partnered & own pre-clinical pipeline

23 INDs
Investigational new drug applications filed by Genmab & partners in 17 years

9 products in clinical development by Genmab and its partners
Daratumumab & ofatumumab in late stage clinical development
Tisotumab vedotin & HuMax®-AXL-ADC in early stage clinical development

2 categories of cancer
Generate products to treat both solid tumors & hematological cancers

3 office locations
Facilities in Denmark, the Netherlands & USA

>200 FTE
Highly experienced & skilled employees

DKK
70.8B
2016 year end market cap

DKK
763M
2016 operating expenses
32% increase versus 2015

DKK
1,816M
2016 revenue
60% increase versus 2015

DKK
3,922M
2016 year end cash position

Operating Result
MDKK



2017 Guidance

Income Statement	DKKM	USDM*
Revenue	1,900 – 2,150	299 - 330
Operating expenses	(1,000) – (1,100)	(153) – (169)
Operating income	900 – 1,100	138 - 169
Cash position at end of year*	>4,500	>691

*Cash, cash equivalents, and marketable securities
USD 1.00 = DKK 6.5165

Our Three-pronged Strategy
Focus on core competence
Turn science into medicine
Build a profitable & successful biotech

Executive Management:

Jan G. J. van de Winkel
Ph.D. President & CEO

David A. Eatwell FCCA
Executive Vice President & CFO

Judith Klimovsky M.D.
Executive Vice President & CDO

Founded: 1999, IPO: 2000
Exchange: NASDAQ
OMX Copenhagen A/S

Symbol:
GEN

ADR ticker Symbol:

GMXAY

Stock information as of August 8, 2017:

Market cap:
~DKK 85 Bn (~USD 13,516 M)

Shares outstanding:
61,118,402

For more information: genmab.com or contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications (+45)33447720

Robust Product Pipeline and Passion for Innovation

Further Development for Marketed Products

Product	Disease Indications	Development Phase: Pre-clinical / I / II / III
Daratumumab BTD Target: CD38, Partner: Janssen	Multiple myeloma (MM)	
	Amyloidosis	
	Natural Killer/T-Cell lymphoma (NKTCL), Nasal Type	
	Myelodysplastic Syndromes (MDS)	
	Solid tumors	
Ofatumumab Target: CD20, Indication: Cancer Partner: Novartis	Follicular lymphoma (FL)	
Ofatumumab (OMB157) Target: CD20, Indication: AI Partner: Novartis	Relapsing multiple sclerosis (RMS) (SubQ)	

Antibody Powerhouse

Product	Disease Indications	Development Phase: Pre-clinical / I / I/II / II / III
Tisotumab vedotin Target: TF	Solid Cancers	
HuMax-AXL-ADC Target: AXL	Solid Cancers	
Teprotumumab (RV001) BTD Target: IGF-1R Partner: River Vision	Graves' orbitopathy	
AMG 714 Target: IL-15 Partner: Celimmune (sublicensed from Amgen)	Celiac Disease	
ADCT-301 (HuMax-TAC-ADC) Target: CD25 Partner: ADCT	Lymphoma	
	Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)	
JNJ-61186372 Targets: EGFR, cMET Partner: Janssen	Non-small-cell lung cancer (NSCLC)	
JNJ-63709178 Targets: CD3, CD123, Partner: Janssen	Acute Myeloid Leukemia (AML)	
JNJ-64007957 Targets: BCMA, CD3 **Partner: Janssen**	Relapsed or refractory MM	
> 20 Active Pre-clinical programs incl., HexaBody-DR5/DR5, DuoBody CD3xCD20	Proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody	
	Partnered programs: HuMab, DuoBody & HexaBody	

At-A-Glance – SELECTED PRODUCTS

DARZALEX® (daratumumab)
- First-in-class CD38 antibody in dev. to treat cancer
- Approved in combo. w/ other therapies in re-lapsed/refractory MM & as monotherapy for heavily pretreated or double-refractory MM in the U.S.
- Approved in Europe in combo. w/ other therapies in relapsed/refractory MM & as monotherapy for heavily pretreated or double-refractory MM
- Studies ongoing for all stages of MM & in solid tu-mors
- Collaboration with Janssen
- 2016 net sales by Janssen were $572M

Tisotumab vedotin
- Antibody-drug conjugate (ADC, antibody coupled to a cell-killing agent) in development to treat solid tu-mors
- 2 PH I/II clinical studies in solid tumors ongoing
- License and collaboration with Seattle Genetics

HuMax®-AXL-ADC
- ADC in development to treat solid tumors
- Ph I/II clinical study for solid tumors ongoing

Arzerra ® (ofatumumab)
- Human CD20 antibody in dev. to treat cancer & au-toimmune disease
- Approved in certain territories for certain CLL indi-cations
- 2 Ph III studies w/ low dose subcutaneous in RMS ongoing
- Collaboration with Novartis
- 2016 net sales by Novartis were $46M

Pre-Clinical Programs
- Broad pre-clinical pipeline of >20 programs includ-ing HexaBody-DR5/DR5 & DuoBody-CD3xCD20
- Pre-clinical pipeline includes both partnered prod-ucts & in-house programs based on our proprietary technologies
- Multiple INDs expected to be submitted over com-ing years

TECHNOLOGIES

DuoBody® Platform
- Genmab's proprietary bispecific antibody tech. plat-form
- Potential application in cancer, autoimmune, infec-tious, cardiovascular & CNS diseases
- Multiple ongoing collaborations incl. with Novartis, Novo Nordisk, Gilead & Janssen Biotech

HexaBody® Technology
- Genmab's proprietary enhanced potency antibody tech. platform
- Broadly applicable tech. builds on natural antibody biology
- Pre-clinical proof-of-concept achieved
- Multiple research collaborations

Antibody-Drug Conjugates
- Monoclonal antibodies w/ potent toxic agents cou-pled to them
- Expanding development area or cancer immuno-therapy

Antibody Generation Technology Platforms
- UltiMab transgenic mouse technology
- OmniAb transgenic mouse & rat platforms
- MAB Discovery's rabbit antibody platform

Read more*
Products in development, Daratumumab, Ofatumumab, Tisotumab vedotin, HuMax-AXL-ADC, Pre-clinical programs, Technologies